1,508 results on '"Becker, Jürgen C."'
Search Results
152. REINA - Retrospective Multicenter ADOReg Evaluation of Ipilimumab plus Nivolumab in Avelumab-refractory Merkel cell carcinoma
153. Expression von DNA-Mismatch-Reparaturproteinen bei Melanompatienten, die mit Immun-Checkpoint-Inhibitoren behandelt werden
154. Waiving Subsequent Complete Lymph Node Dissection in Melanoma Patients with Positive Sentinel Lymph Node Does Not Result in Worse Outcome on 20-Year Analysis
155. Self-reactive T cells: suppressing the suppressors
156. Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter Analysis
157. DNA-methylation patterns imply a common cellular origin of virus- and UV-associated Merkel cell carcinoma
158. Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
159. Mismatch Repair Protein Expression and Microsatellite Instability in Cutaneous Squamous Cell Carcinoma
160. Reversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinoma
161. Aggressive primary cutaneous B-cell lymphomas show increased Angiopoietin-2-induced angiogenesis
162. Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma
163. Fluorescence in situ hybridization and qPCR to detect Merkel cell polyomavirus physical status and load in Merkel cell carcinomas
164. Presence of Human Polyomavirus 6 in Mutation-Specific BRAF Inhibitor–Induced Epithelial Proliferations
165. Immune-suppressive properties of the tumor microenvironment
166. Tumor-associated antigens characterized in a conceptual framework of biology, microenvironment, and therapy
167. Cellular and cytokine-dependent immunosuppressive mechanisms of grm1-transgenic murine melanoma
168. Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma
169. Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer
170. Expression of Mismatch Repair Proteins in Merkel Cell Carcinoma
171. A phase II, open-label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel cell carcinoma progressing on anti-PD-(L)1 antibody therapy: The MERKLIN 2 study.
172. New Insights into the Biological and Clinical Aspects of Merkel Cell Carcinoma
173. Expression of mismatch repair proteins in merkel cell carcinoma
174. Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer.
175. Expression of potential targets for cell-based therapies on melanoma cells
176. Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors
177. Prof. Dr. Jürgen C. Becker an das Westdeutsche Tumorzentrum Essen berufen
178. Tumor-educated myeloid cells: impact the micro- and macroenvironment
179. The immunodominant HLA-A2-restricted MART-1 epitope is not presented on the surface of many melanoma cell lines
180. Malignant T cells induce skin barrier defects through cytokine-mediated JAK/STAT signaling in cutaneous T-cell lymphoma
181. Cancer treatment: the combination of vaccination with other therapies
182. Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy
183. Merkel-Zell-Karzinom
184. The HDAC Inhibitor Domatinostat Promotes Cell-Cycle Arrest, Induces Apoptosis, and Increases Immunogenicity of Merkel Cell Carcinoma Cells
185. Expression of Potential Targets for Cell-Based Therapies on Melanoma Cells
186. Ralph A. Reisfeld, PhD: In Memoriam (1926–2020)
187. Mutational Landscape of Virus- and UV-Associated Merkel Cell Carcinoma Cell Lines Is Comparable to Tumor Tissue
188. Anti-cancer therapies targeting the tumor stroma
189. Immunological tumor destruction in a murine melanoma model by targeted LTα independent of secondary lymphoid tissue
190. Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma
191. The Janus-faced role of KDM5B heterogeneity in melanoma: differentiation as a situational driver of both growth arrest and drug-resistance
192. Therapeutic efficacy of tumor-targeted IL2 in LTα−/− mice depends on conditioned T cells
193. Identification of identical TCRs in primary melanoma lesions and tumor free corresponding sentinel lymph nodes
194. Tumor stroma-associated antigens for anti-cancer immunotherapy
195. MicroRNAs in the Pathogenesis, Diagnosis, Prognosis and Targeted Treatment of Cutaneous T-Cell Lymphomas
196. Staphylococcus aureus alpha-toxin inhibits CD8+ T cell-mediated killing of cancer cells in cutaneous T-cell lymphoma
197. Staphylococcus aureus enterotoxins induce FOXP3 in neoplastic T cells in Sézary syndrome
198. Stromal cells as the major source for matrix metalloproteinase-2 in cutaneous melanoma
199. Cytoplasmic and nuclear expression of survivin in melanocytic skin lesions
200. Regulators of apoptosis: suitable targets for immune therapy of cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.